15 Medical Innovation Companies Seek Funding in Biotech, Medical Imaging, and SaaS Platforms – National Day Special Roundup
- VCBeat “Supply-Demand Matchmaking”Industry Linkage Platform,Efficiently Connect with Industry Resources to Drive Performance Growth
- Nearly 1,000 supply and demand information listings have been launched online, with the cumulative number of successful enterprise matchings exceeding2,000 times
- ContinuousCurated Supply and Demand Information Collection Released, with Precise PushDistributed to VCBeat’s relevant industry communities (with a total reach of over3W+）
According to statistics, a total of occurred in the domestic healthcare and wellness sector in the first half of 2024696 casesInvestment and financing events (excluding M&A, private placements, and equity transfers) increased by 2.20% compared to the 681 deals recorded in the same period of 2023 (data sourced from Yuanshi Capital). Currently, the pharmaceutical industry is developing steadily, driven by multiple factors including innovation-driven growth, international expansion, national policy support, technological advancements, and consumption upgrades. Several medical technology companies have announced financing and cooperation plans. VCBeatCurated Supply-Demand Matchmaking Links – National Day Special, this issueBringing You Multiple Innovative EnterprisesFinancing Needs。Details are as follows:
●Company/Product Introduction：
Bishengpu Biotechnology Co., Ltd. is the undisputed global leader in the field of high-frequency QRS technology. Its Israeli subsidiary, BSP, has been engaged in basic research and clinical trials on high-frequency QRS for over 20 years, accumulating more than 60 patented inventions worldwide. Our company’s HyperQ high-frequency QRS technology for detecting myocardial ischemia is exclusive globally with no competitors, and has obtained regulatory approvals in China, the United States, and Europe. We have published over 40 SCI-indexed clinical academic papers in top-tier cardiovascular journals worldwide. Leading domestic experts have issued the world’s first expert consensus specifically based on this technology, underscoring its significant clinical value. The technology was awarded the highest prize in the biological sector at the "Second China Disruptive Technology Innovation Competition" organized by the Ministry of Science and Technology in 2022, was included in the major special project guidelines of the Central Military Commission's Science and Technology Commission in 2023, and received special approval from the China Astronaut Research and Training Center in 2024, with plans to be deployed on the space station in 2025. We are currently conducting post-market clinical studies with dozens of top-tier hospitals in China (including Peking Union Medical College Hospital, PLA General Hospital (301), Fuwai Hospital, Anzhen Hospital, West China Hospital, Ruijin Hospital, Guangdong Provincial People's Hospital, Sun Yat-sen Memorial Hospital, Huazhong Union Hospital, Tongji Hospital, Qilu Hospital, Sir Run Run Shaw Hospital of Zhejiang University, Xiangya Hospital, etc.), positioning the technology on the eve of large-scale clinical application.
● Collaboration Requirements:
We are currently seeking investment firms that specialize in early-stage medical devices to help us achieve rapid market commercialization. As we are on the verge of an explosive growth phase, we require well-capitalized investors to enter the landscape promptly.
●Company/Product Introduction：
Renyuan Biotechnology, founded by Dr. Zhang Lei in 2023, is an innovative company dedicated to the development of stem cell therapies for vascular repair. Leveraging its proprietary vascular repair stem cell technology, Renyuan Biotechnology has established a leading R&D platform with broad application potential for such therapies. The company has laid out four major product pipelines in the cardiovascular and cerebrovascular fields, specifically comprising three drug candidates—VCP01, VCP02, and VCP03—for the treatment of cardiovascular and cerebrovascular diseases, as well as the MV3D-01 3D vascular chip series. The VCP01/02/03 product series is expected to file Investigational New Drug (IND) applications in 2025.
● Collaboration Requirements:
Leveraging its proprietary vascular repair stem cell technology, Renyuan Biotechnology provides technical services to research institutions and downstream enterprises, thereby advancing research and progress in related fields. Renyuan Biotechnology is scheduled to initiate a new round of financing by the end of 2024 to support Investigational New Drug (IND) applications and R&D for its core pipeline. Investment institutions interested in Renyuan Biotechnology and its technological products are welcome to engage in discussions immediately.
● Company/Product Introduction:
Puyuan Biotech is rooted in microbiome research, focusing on the frontiers of neuroimmunology and gut microbiota, to develop and manufacture probiotics and related products.
Puyuan Biologics has established a pipeline of four live biotherapeutic product candidates, including Pm001, Pm002, BW002, and Dm008, targeting indications such as inflammatory bowel disease, ankylosing spondylitis, liver injury, and type 2 diabetes. Among these, Pm001, Pm002, and BW002 have all entered the preclinical research stage, with Pm001 expected to obtain Investigational New Drug (IND) approval in 2025.
● Collaboration Requirements:
Puyuan Biotechnology is launching a new round of financing. If any investment institutions are interested in Puyuan Biotechnology and its technological products, please feel free to contact us immediately.
● Company/Product Introduction:
Shengxing Medical, established in June 2021, is a high-tech enterprise dedicated to the research and development of holographic preoperative planning systems for medical imaging and holographic intelligent surgical navigation and guidance systems. Leveraging its profound expertise in virtual reality and healthcare, the company has rapidly attained recognition as a National High-Tech Enterprise, a Specialized, Refined, Differential, and Innovative (SRDI) Enterprise, a Zhongguancun Golden Seed Enterprise, and a Zhongguancun High-Tech Enterprise. It has also secured China’s first VR medical device registration certificate issued by the National Medical Products Administration (NMPA) and the country’s first holographic medical imaging registration certificate (NMPA).
In 2021, Shengxing Medical’s self-developed “Medical Image Processing and VR Display Operating System” obtained China’s first VR medical device registration certificate. To date, the company has partnered with more than 20 hospitals across China, where the product has been deployed for clinical use.
In 2024, the company’s independently developed “Holographic Intelligent Multimodal Fusion Imaging Surgical Navigation System” is set to receive NMPA approval.
● Collaboration Requirements:
Shengxing Medical is seeking NMPA approval and market expansion for its core products; meanwhile, the company is undergoing a new round of financing. If any investment institutions are interested in Shengxing Medical and its technological products, please feel free to contact us immediately.
●Company/Product Introduction：
As a domestically developed, independently innovated dual-pneumatic high-speed vitreous cutter probe, this device is available in 23G, 25G, and 27G specifications, with cutting speeds of 2,500, 5,000, 7,500, and 10,000 cuts per minute (CPM). It is compatible with vitrectomy machines from major brands. As the first manufacturer in China and the second globally to produce a dual-pneumatic vitreous cutter probe with a base cutting speed of up to 10,000 CPM, this achievement marks that China’s medical devices for vitreoretinal surgery have reached an internationally advanced level.
● Collaboration Requirements:
● Company/Product Introduction:
Zhuhai Shenping Medical Co., Ltd. was established in August 2016, with a registered capital of RMB 49.28 million. Located at Gangwan No. 2 Shuangbo Base in the High-Tech Industrial Development Zone of Zhuhai City, the company occupies a manufacturing facility of over 2,000 square meters and is a high-tech enterprise focused on comprehensive medical solutions for stroke.
Shenping Medical is dedicated to providing patients with high-quality, comprehensive solutions for neurointerventional procedures. To ensure the safety and efficacy of its products, the company has established and obtained ISO 13485 quality management system certification. Through years of technological research, development, innovation, and accumulation, Shenping Medical has developed a series of neurointerventional (sub-category) medical devices with independent intellectual property rights. The company holds seven core patents; three of its products have obtained EU CE certification and are being commercialized in over 60 countries, while five products have achieved Brazilian MDSAP certification. These products have received consistent acclaim from clinicians both domestically and internationally. Furthermore, four additional products are expected to obtain registration certificates from China’s National Medical Products Administration (NMPA) by the end of this year.
● Collaboration Requirements:
1. Financing Round and Amount: Initiated Series B financing, with a fundraising amount of RMB 50 million.
2. Use of Proceeds After Financing:
1) Talent Introduction, RMB 5 million, 10.0%
2) Domestic market promotion, RMB 5 million, 10.0%
3) Expanded reproduction, RMB 3 million, 6%
4) Expanded reproduction, RMB 3 million, 6%
5) Others, RMB 1 million, 3%
●Company/Product Introduction：
Wuhan Yuanqi Hirudin Biotechnology Co., Ltd. was jointly established by Beijing Gengtianxia Biotechnology Co., Ltd. and Dr. Hu Changfeng from Tsinghua University.
1) Pioneered a disruptive synthetic biology innovation system using Chlamydomonas as the chassis;
2) There are 12 recombinant protein drugs under development;
3) The first recombinant protein—hirudin—achieved site-specific sulfation modification;
4) Completion of pilot-scale production, with process quality meeting industrial standards;
5) Build the world’s first CDMO platform for recombinant functional proteins.
● Collaboration Requirements:
1. Development Plan:
1) Wuhan: R&D + Pilot Scale-up
3,000 m² R&D Center + 5,000 m² Pilot-Scale Base
Jianghan University’s Science and Technology Innovation Center has allocated an entire floor, totaling 1,500 square meters, for the establishment of the Wuhan Yuanqi Application Development Center, which is scheduled to move in by October 2024.
5,000 m² Production Base to Begin Construction in Q3; Phase I Capacity of 10 Tons
2) Beijing – Global Operations Center
2. Financing Planning:
1) RMB 30 million—This round of financing raises RMB 30 million, with a 20% equity stake in Wuhan Yuanqi being divested, resulting in a post-money valuation of RMB 150 million.
2) Use of Proceeds—Product Development and Qualification Filing 20%, Sales Operations 30%, Hirudin Clinical Trial Application 50%
●Company/Product Introduction：
The company is positioned to build a high-end domestic brand in medical aesthetic optoelectronics. As upstream products in the medical and beauty industry chain, laser medical devices will continue to benefit from overall industry growth, offering substantial market potential. Baifu Group is a high-tech enterprise focused on the high-end laser medical aesthetics sector, with digital and intelligent medical solutions at its core. At present, the company is dedicated to the independent R&D, manufacturing, sales, and scientific research services of innovative products in dermatology, plastic surgery, rehabilitation medicine, and general health. Currently, some of its equipment has achieved breakthroughs in domestic production. The company has independently developed series of ND:YAG Q-switched lasers, 1064 nm long-pulse lasers, 755 nm alexandrite long-pulse lasers, 2940 nm erbium lasers, and 1064 & 532 nm picosecond lasers, with relevant technical indicators reaching a leading level in China. Its products have obtained CE, FDA, and NMPA certifications and are exported to more than 60 countries and regions.
●Collaboration Requirements:
Baifu Laser has currently launched its Series B+ funding round, with the amount raised not exceeding RMB 50 million.
●Company/Product Introduction：
Meishangjie Biotechnology Co., Ltd. has achieved significant breakthroughs in the field of gene editing, driven by its forward-looking R&D philosophy and leading technological capabilities. The company’s proprietary recombinant gene editing technology ingeniously combines recombinant collagen with recombinant fibronectin to create a unique microcapsule structure. This approach not only preserves the biological activity of collagen but also enhances its penetration and stability within the skin. Meishangjie has further evolved this innovation into a comprehensive technical platform with the potential to develop proteins tailored for various parts of the human body.
Currently, the company has successfully developed recombinant human BMP-2 protein, recombinant human GDF-11/BMP-11 protein, and recombinant metallothionein. These recombinant proteins hold broad application prospects and significant potential value in the fields of medicine and biotechnology.
●Collaboration Requirements:
In the first half of 2024, Jiangsu Meishangjie Biotechnology Co., Ltd. successfully secured tens of millions of RMB in Series A financing. The round was led by Shanghai Jiushong Shanhe Investment, with participation from Zhangjiagang Jinxin Capital and Zhangjiagang City Fund’s Zhangchuangtou.
To further increase investment in R&D and market expansion, continuously enhance the core competitiveness of its products, and expand market share, a new round of financing has been launched, with Xuyi Capital serving as the financial advisor.
●Company/Product Introduction：
Xingming Youjian is an ophthalmic drug company incubated by Fuxian Capital, the innovative fund for new drugs under Fuxian. The company focuses on the development of in vivo gene therapy products for ophthalmic diseases, targeting photoreceptor degenerative diseases and optic nerve degenerative diseases., leveraging proprietary optogenetics and in situ transdifferentiation technologies to independently develop optogenetic and optic nerve regeneration AAV gene therapy products.
Over the past three years since its establishment, Xingming Youjian has confirmed lightWith two technological platforms—genetics and neural regeneration—the company has three pipelines under development. The most advanced pipeline has progressed to investigator-initiated trials (IITs), with partial interim results already disclosed, demonstrating excellent safety and efficacy.
●Cooperation Requirements:
The company is currently launching a new round of financing.
●Company/Product Introduction：
Chengdu Feiming Technology Co., Ltd. was established in November 2017 as a wholly-owned subsidiary of Quark Pharma (China) Co., Ltd. As an innovative medical device R&D company, Feiming Technology leverages computer technologies such as virtual reality, computer vision, and big data to develop multiple models of medical devices for "musculoskeletal rehabilitation and neurological rehabilitation."Rehabilitation device products are dedicated to helping patients achieve clinical goals for motor impairment rehabilitation through human-machine intelligence and the integration of exercise and medicine. Currently, there are multiple medical device projects under development.
Virtual Reality-Based Intelligent Rehabilitation Medical Devices Are Primarily Targeted atThe market is divided into two segments: hospital-exclusive and general household use. The company plans to first establish its presence in the hospital-exclusive market, then gradually expand into the home-use sector through hospitals and physicians.
●Collaboration Requirements:
The proceeds from this financing round will be allocated to the research and development of the stroke pipeline, registration and market expansion, expansion of new product sales pipelines, and the introduction of new technologies.
●Company/Product Introduction：
The company focuses on the fields of neurosurgery and interventional procedures, dedicated to enhancing the precision and standardization of clinical surgeries while reducing operational risks. The management team possesses over 10 years of experience in the neurology industry, and the core R&D team has comprehensive experience in the full-cycle development of medical device products. The company holds more than 70 patent applications.
The company’s competitive differentiation lies in achieving low-cost domestic substitution through technological innovation, with pricing at one-sixth that of comparable competitors.
●Collaboration Requirements:
The company is currently seeking financing; interested investment institutions are welcome to contact us for further discussion.
●Company/Product Introduction：
Infomei focuses on the specialized vertical field of comprehensive kidney diseases, aiming to build a 360° all-around data management platform. In addition to the electronic medical record (EMR) system for hemodialysis, the company has concurrently developed EMR systems for peritoneal dialysis and continuous renal replacement therapy (CRRT). Together, these three components form the i-DiaPro integrated data management platform for blood purification. The company has also developed China’s first kidney disease follow-up mobile application, “Yaoguo Doctor,” which serves as a doctor-patient communication platform bridging out-of-hospital and in-hospital care. The app integrates a nephrology drug dictionary containing medication information related to kidney diseases, covering all common chronic conditions and various types of renalinflammation, syndrome, renal failure, and other specialized knowledge; on the platform, physicians can conduct follow-up assessments with patients anytime and anywhere, freely customize questionnaire templates suitable for all chronic kidney diseases, perform data entry through form filling, automatically recognize laboratory test results, and easily complete follow-up tasks.follow-up work, while the system itself can also conduct multi-dimensional statistical analysis of data to support scientific research and policy formulation.
●Collaboration Requirements:
Industry’s First Class III Registered Innovative Medical Device Software: Novel AI-Based Non-Invasive Real-Time Biochemical Assessment Technology for Blood Purification—Seeking Market Collaboration and Series B Financing.
●Company/Product Introduction：
Antis’s rhythmic deep brain-accessible low-intensity transcranial magnetic stimulation technology (hereinafter referred to as rDMS) holds global patents. Product development has been completed, and the company has long collaborated with numerous experts and scholars in the fields of neuroscience and brain disorders both domestically and internationally.Collaboration has completed extensive basic and clinical research, with results supporting the immediate initiation of clinical trials for medical device registration.Effective prevention and treatment of insomnia, depression, and AD.
Antis will contribute mainstream intervention approaches originating from China to the prevention and treatment of major brain diseases in humans.
●Cooperation Requirements:
Pre-Series A: RMB 30 million
Series A: $15 million
●Company/Product Introduction：
Project Progress: The software and hardware development for the supply chain management system tailored to private dental clinics has been completed, resulting in 9 patents (including 2 invention patents) and 10 software copyrights. The supply chain procurement platform is currently under construction. To date, the system has been deployed in 10 clinics, with nearly 100 additional installation orders pending. Funding is required to procure hardware and produce/install the necessary equipment for these clinics. It is estimated that each clinic will generate annual consumables sales exceeding RMB 200,000.
Project Highlights: Leveraging advanced Internet of Things (IoT) technology, this solution enables end-to-end digital real-time tracking of clinic consumables—from procurement scheduling and delivery to inventory management. This approach mitigates negative impacts caused by manual management inefficiencies, such as overstocking, operational disarray, material loss, supplier mismanagement, and expiration of supplies. It truly facilitates the digital and intelligent transformation of private clinics, achieving refined operational management.
Technical Highlights:Leveraging SaaS platform technology to reduce clinic operating costs and enable unified management of multi-site deployments; utilizing the most advanced Internet of Things (IoT) technology,Enables full lifecycle traceability management of medical consumables, facilitating inspections by drug regulatory authorities; employs AI-powered image recognition technology to intelligently read inbound and outbound documents, truly achieving paperless and convenient operations.
● Collaboration Requirements:
Seeking Pre-A Round Financing of 5 Million
Scan the QR code below to access a vast network of links with a single click.
- VCBeat Supply and Demand Matching Platform covers: global expansion, supply chain, marketing/channels, technology transfer, and investment promotion/onboarding.
- Upload supply or demand resources on the platform to precisely reach targeted prospective partners
- Efficiently connect with MNCs, startups, government industrial parks, investment institutions, and other entities
>>>>
Download the VCBeat app to publish independently and connect efficiently.
